The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
13-Jul-12
$NA
Target:
Timberland Assets of Forest Capital Partners, LLC
Acquiror:
Hancock Timber Resources Group and Molpus Woodlands Group
Advised Hancock Timber Resources Group, the largest Timber Investment Management Organization globally and a subsidiary of Hancock Natural Resource Group, Inc., and Molpus Woodlands Group on the acquisition of 1.9 million acres of timberlands from Forest Capital Partners, LLC
26-Apr-12
$1.8 billion
Target:
Retail Propane Operations of Inergy, L.P.
Acquiror:
Suburban Propane Partners, L.P.
Advised Inergy, L.P., a master limited partnership with propane and midstream natural gas operations, on the sale of its retail propane operations to Suburban Propane Partners, L.P., a national propane retailer
23-Apr-12
$2.0 billion
Target:
Moorebank Intermodal Terminal
Acted as independent advisor to the Australian Government in a peer review of the proposed intermodal terminal linking Sydney’s major port with Australia’s road and rail system
26-Mar-12
$513 million
Target:
ISTA Pharmaceuticals, Inc.
Acquiror:
Bausch + Lomb, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company
20-Jan-12
$NA
Target:
Solar PV power plant in Italy
Acquiror:
Antin Infrastructure Partners
Advised Antin Infrastructure Partners on the acquisition of a c.20MW solar PV power plant in Italy
16-Dec-11
$NA
Target:
ISTA Pharmaceuticals, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives
21-Nov-11
$689 million
Target:
iNova Pharmaceuticals
Acquiror:
Valeant Pharmaceuticals
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
07-Nov-11
$398 million
Target:
American Dental Partners, Inc.
Acquiror:
JLL Partners
Advised American Dental Partners, Inc. (NASD: ADPI), one of the nation’s leading business partners to dental group practices, on its sale to JLL Partners, a leading private equity firm
10-Oct-11
$3.2 billion
Target:
Complete Production Services
Acquiror:
Superior Energy Services
Advised Superior Energy Services on its acquisition of Complete Production Services, a leading provider of oilfield services in North America
14-Jul-11
$340 million
Target:
Edge Oilfield Services
Acquiror:
Key Energy Services, Inc.
Advised Key Energy Services, the largest onshore, rig-based well servicing contractor, on its acquisition of Edge Oilfield Services, a provider of onshore oilfield rental equipment
30-Jun-11
$609 million
Target:
Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion
Acquiror:
Royalty Pharma
Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion
20-Jun-11
$2.0 billion
Target:
Capital Power Income L.P.
Acquiror:
Atlantic Power Corporation
Advised Capital Power Income L.P., a Canadian power trust with a portfolio of 20 power generation assets located in Canada and the United States (total net generating capacity of 1,400 MW), on its sale to Atlantic Power Corporation
06-May-11
$NA
Target:
Aker Solutions (Aker Holding)
Acquiror:
Norwegian Government
Advised the Norwegian Government on strategic and financial matters in relation to its investment in Aker Holding, the largest shareholder of Aker Solutions during the demerger of the company’s EPC activities
02-Mar-11
$NA
Target:
TSmarine
Acquiror:
Fugro N.V.
Advised CHAMP Ventures on the sale of its portfolio company TSmarine, a provider of subsea services to the offshore oil and gas industry, to Fugro, among the world's leading service providers for the collection and interpretation of data relating to the earth's surface and sub-surface and for associated services
15-Dec-10
$4.6 billion
Target:
Dynegy Inc.
Acquiror:
Icahn Enterprises LP
Advised Dynegy Inc., an independent power producer, on its sale to Icahn Enterprises LP in an all-cash transaction
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
13-Dec-10
$256 million
Target:
Maxinutrition Group Holdings Limited
Acquiror:
GlaxoSmithKline Plc
Advised GlaxoSmithKline Plc, the UK listed international pharmaceutical and consumer company, on its acquisition of Maxinutrition Group Holdings Limited, a UK based sports nutrition business, from Darwin Private Equity
07-Dec-10
$500 million
Target:
Medicity, Inc.
Acquiror:
Aetna Inc.
Advised Aetna Inc. on its acquisition of Medicity, Inc., a leading provider of technology solutions to enable the secure access and exchange of healthcare information
26-Nov-10
$118 million
Target:
Healthcare Australia
Acquiror:
Healthcare Locums
Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK
21-Sep-10
$234 million
Target:
Taro Pharmaceutical Industries
Acquiror:
Sun Pharmaceutical Industries Ltd.
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
12-Jul-10
$NA
Target:
Breast Care Business of Ethicon-Endo Surgery
Acquiror:
Devicor Medical Products, Inc. (a GTCR portfolio company)
Advised GTCR and Devicor Medical Products, Inc., a portfolio company of GTCR, on the acquisition of the Breast Care Business of Ethicon-Endo Surgery
07-Jul-10
$1.8 billion
Target:
Viridian
Acquiror:
ESB
Advised Viridian, one of the leading electricity companies in the all Ireland market, on the sale of NIE, its regulated electricity transmission and distribution businesses in Northern Ireland, to ESB, the state owned vertically integrated utility in Republic of Ireland
05-Apr-10
$225 million
Target:
Medegen, Inc
Acquiror:
CareFusion Corporation
Advised Medegen, Inc., a medical device company that develops, manufactures and markets clinically superior disposable intravenous therapy products on its sale to CareFusion, a global medical devices company
03-Mar-10
$NA
Target:
Puerta Mexico Transportation Facility
Acquiror:
Kansas City Southern
Advised Ports America, Inc., a portfolio company of Highstar Capital, on its sale of Puerta Mexico, a state-of-the-art customs-clearing intermodal transportation facility located in the Mexico City market
23-Feb-10
$NA
Target:
Heartscape Technologies, Inc.
Acquiror:
Roper Industries, Inc.
Advised Heartscape Technologies, a medical device company on its sale of substantially all its assets to Roper Industries, a diversified growth company